SOUTH PLAINFIELD, N.J., April 2, 2012 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced the promotions of Claudia Hirawat to President and Mark Boulding to Executive Vice President and Chief Legal Officer.
"I am extremely pleased to announce these promotions. Claudia has made significant contributions to the growth and development of PTC since she joined the company, providing leadership across multiple areas. Mark has been a strategic partner in all aspects of the business throughout the years and I look forward to the continuity and guidance his expanded role will provide," commented Stuart Peltz, Ph.D., Chief Executive Officer of PTC Therapeutics, Inc. "The goal of this new structure is to streamline our management efforts and increase efficiency in all operational and strategic efforts of the company for the next stage of our development."
Ms. Hirawat joined PTC in 2000 and was most recently Senior Vice President of Corporate Development. In addition to leading the business development efforts, which have brought PTC $207 million in upfront payments alone, Ms. Hirawat has been involved in all aspects of PTC's operational development, fundraising efforts and strategic planning. Prior to PTC, Ms. Hirawat was a Vice President at LedbetterStevens, a management consulting and senior-level retained search firm in New York focused exclusively in the biopharmaceutical area.
Mr. Boulding was most recently Senior Vice President and General Counsel. Since joining PTC in 2002, he has negotiated multiple financing rounds, license agreements and strategic partnerships for PTC, as well as overseeing the development of the company's intellectual property portfolio. Prior to joining PTC, Mr. Boulding was the General Counsel and Executive Vice President, Government and Regulatory Affairs of MedicaLogic/Medscape, Inc., a publicly-traded company. Before Medscape, Mr. Boulding was a law firm partner in private practice in Washington, DC specializing in healthcare and technology law, with a focus on pharmaceutical, biotech and high-tech companies.
About PTC Therapeutics, Inc.
PTC is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered small-molecule drugs that target post-transcriptional control processes. Post-transcriptional control processes regulate the rate and timing of protein production and are of central importance to proper cellular function. PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare genetic disorders, oncology and infectious diseases. PTC has developed proprietary technologies that it applies in its drug discovery activities and that have served as the basis for collaborations with leading biopharmaceutical companies such as AstraZeneca, Celgene, Genzyme, Merck, Pfizer and Roche. For more information, visit the company's website at www.ptcbio.com.
SOURCE PTC Therapeutics, Inc.